Aktienanalyse zu Penumbra Inc (PEN)PENPenumbra Inc

Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Penumbra Inc is a good buy right now due to its strong revenue growth and improving gross margins. The current price is $320.86, which is about 13% below the average analyst price target of $350. Additionally, the gross margin for Q2 2026 is 67.9%, indicating solid profitability. The main risk is the recent earnings miss, with an EPS of $0.88 reported against an estimate of $1.15, reflecting a surprise of -23.48%.

5 analysts cover PEN: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 344.64.